CN107840847A - 氘代3‑(4,5‑取代氨基嘧啶)苯基衍生物及其应用 - Google Patents
氘代3‑(4,5‑取代氨基嘧啶)苯基衍生物及其应用 Download PDFInfo
- Publication number
- CN107840847A CN107840847A CN201610833361.3A CN201610833361A CN107840847A CN 107840847 A CN107840847 A CN 107840847A CN 201610833361 A CN201610833361 A CN 201610833361A CN 107840847 A CN107840847 A CN 107840847A
- Authority
- CN
- China
- Prior art keywords
- compound
- cancer
- egfr
- pharmaceutically acceptable
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 substituted-amino pyrimidine Chemical class 0.000 title abstract description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 87
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 8
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims abstract 6
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims abstract 6
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims abstract 6
- 239000003814 drug Substances 0.000 claims description 25
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 13
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 13
- 230000003213 activating effect Effects 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 230000001404 mediated effect Effects 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 4
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 210000002919 epithelial cell Anatomy 0.000 claims description 4
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 201000006845 reticulosarcoma Diseases 0.000 claims description 4
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 2
- WLXGQMVCYPUOLM-UHFFFAOYSA-N 1-hydroxyethanesulfonic acid Chemical compound CC(O)S(O)(=O)=O WLXGQMVCYPUOLM-UHFFFAOYSA-N 0.000 claims description 2
- QEVGZEDELICMKH-UHFFFAOYSA-L 2-(carboxylatomethoxy)acetate Chemical compound [O-]C(=O)COCC([O-])=O QEVGZEDELICMKH-UHFFFAOYSA-L 0.000 claims description 2
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 claims description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 2
- 241000723346 Cinnamomum camphora Species 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 claims description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 2
- 229940072107 ascorbate Drugs 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229940009098 aspartate Drugs 0.000 claims description 2
- 229940077388 benzenesulfonate Drugs 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 2
- 229940050390 benzoate Drugs 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 claims description 2
- 229960000846 camphor Drugs 0.000 claims description 2
- 229930008380 camphor Natural products 0.000 claims description 2
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 claims description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 claims description 2
- 229940043264 dodecyl sulfate Drugs 0.000 claims description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 claims description 2
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 229940075930 picrate Drugs 0.000 claims description 2
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 claims description 2
- 229950010765 pivalate Drugs 0.000 claims description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 2
- 229960001860 salicylate Drugs 0.000 claims description 2
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 229920002230 Pectic acid Polymers 0.000 claims 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 238000002965 ELISA Methods 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 41
- 102000001301 EGF receptor Human genes 0.000 description 32
- 108060006698 EGF receptor Proteins 0.000 description 32
- 239000007787 solid Substances 0.000 description 29
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 239000002904 solvent Substances 0.000 description 24
- 238000004809 thin layer chromatography Methods 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 21
- 230000002829 reductive effect Effects 0.000 description 20
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 238000004440 column chromatography Methods 0.000 description 17
- 229940079593 drug Drugs 0.000 description 17
- 239000003112 inhibitor Substances 0.000 description 17
- 239000002994 raw material Substances 0.000 description 17
- 238000003756 stirring Methods 0.000 description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 238000012544 monitoring process Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- PTNZGHXUZDHMIQ-UHFFFAOYSA-N 4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2C(C)C(C(O)C3C(C(O)=C(C(N)=O)C(=O)C3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-UHFFFAOYSA-N 0.000 description 9
- 229960004082 doxycycline hydrochloride Drugs 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000007858 starting material Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000001035 drying Methods 0.000 description 7
- 239000003480 eluent Substances 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 206010059866 Drug resistance Diseases 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 229940121649 protein inhibitor Drugs 0.000 description 6
- 239000012268 protein inhibitor Substances 0.000 description 6
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 229960003278 osimertinib Drugs 0.000 description 5
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- INUNLMUAPJVRME-UHFFFAOYSA-N 3-chloropropanoyl chloride Chemical compound ClCCC(Cl)=O INUNLMUAPJVRME-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000003566 phosphorylation assay Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 3
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000012295 chemical reaction liquid Substances 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 229940125810 compound 20 Drugs 0.000 description 3
- 229940126208 compound 22 Drugs 0.000 description 3
- 229940125833 compound 23 Drugs 0.000 description 3
- 229940125961 compound 24 Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 229940121647 egfr inhibitor Drugs 0.000 description 3
- 210000003722 extracellular fluid Anatomy 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 238000004537 pulping Methods 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- 206010048610 Cardiotoxicity Diseases 0.000 description 2
- 101150039808 Egfr gene Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- 102000004257 Potassium Channel Human genes 0.000 description 2
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 231100000259 cardiotoxicity Toxicity 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 108700021358 erbB-1 Genes Proteins 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 108020001213 potassium channel Proteins 0.000 description 2
- 230000002336 repolarization Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 1
- XNIOWJUQPMKCIJ-UHFFFAOYSA-N 2-(benzylamino)ethanol Chemical compound OCCNCC1=CC=CC=C1 XNIOWJUQPMKCIJ-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- FYSIGSQCZXQTIH-UHFFFAOYSA-N 4-fluoro-2-methoxy-5-nitroaniline Chemical compound COC1=CC(F)=C([N+]([O-])=O)C=C1N FYSIGSQCZXQTIH-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- AZWYVTAQBOKVTA-UHFFFAOYSA-N CC(C)(C)OC(NCCN(C)Cc1ccccc1)=O Chemical compound CC(C)(C)OC(NCCN(C)Cc1ccccc1)=O AZWYVTAQBOKVTA-UHFFFAOYSA-N 0.000 description 1
- 0 CN(C)CCN(*)c(c(N)c1)cc(OC)c1Nc1nccc(-c2c[n](CCC3)c4c3cccc24)n1 Chemical compound CN(C)CCN(*)c(c(N)c1)cc(OC)c1Nc1nccc(-c2c[n](CCC3)c4c3cccc24)n1 0.000 description 1
- LIUGRXFEJOSPIA-UHFFFAOYSA-N CN(CCN)Cc1ccccc1 Chemical compound CN(CCN)Cc1ccccc1 LIUGRXFEJOSPIA-UHFFFAOYSA-N 0.000 description 1
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 238000003649 HTRF KinEASE Methods 0.000 description 1
- 102000040104 IAP family Human genes 0.000 description 1
- 108091069885 IAP family Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000000887 Transcription factor STAT Human genes 0.000 description 1
- 108050007918 Transcription factor STAT Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960003235 allopurinol sodium Drugs 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000012820 cell cycle checkpoint Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 229950002205 dacomitinib Drugs 0.000 description 1
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000004656 dimethylamines Chemical class 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000002834 estrogen receptor modulator Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960003359 palonosetron hydrochloride Drugs 0.000 description 1
- OLDRWYVIKMSFFB-SSPJITILSA-N palonosetron hydrochloride Chemical compound Cl.C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 OLDRWYVIKMSFFB-SSPJITILSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000849 selective androgen receptor modulator Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- PTJRZVJXXNYNLN-UHFFFAOYSA-M sodium;2h-pyrazolo[3,4-d]pyrimidin-1-id-4-one Chemical compound [Na+].[O-]C1=NC=NC2=C1C=NN2 PTJRZVJXXNYNLN-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000003558 transferase inhibitor Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一类氘代3‑(4,5‑取代氨基嘧啶)苯基衍生物及其应用,其为具有式(I)结构的化合物或其药学上可接受的盐,这些化合物或其盐可通过某些突变形式的表皮生长因子受体而用于疾病或病况的治疗或预防,可以有效抑制多种肿瘤细胞的生长,并对EGFR、Her家族其他蛋白酶产生抑制作用,可用于制备抗肿瘤药物。
Description
技术领域
本发明属于抗肿瘤药物技术领域,具体涉及氘代3-(4,5-取代氨基嘧啶)苯基衍生物及其在制备抗肿瘤药物中的应用。
背景技术
在传统的癌症治疗过程中,化疗为主要的治疗手段;化疗药物非特异性地阻断细胞***从而使细胞死亡,它们在杀死肿瘤细胞的同时,也大大破坏了人体正常细胞的生长,带来许多不良反应。很多人因为担忧化疗的严重副作用而使心情悲观甚至放弃治疗,再加上化疗药物的耐药性,使非小细胞肺癌(NSCLC)的化疗不容乐观,而延长化疗的周期只增加了毒副作用,并没有增加疗效。同时非小细胞肺癌的癌细胞对化疗、常规化疗不敏感,总缓解率也只有25%左右;由于这些原因的限制,非小细胞肺癌患者五年生存率低于20%。
在50%-80%的NSCLC病人中,他们的表皮生长因子受体(epidermal growthfactor receptor,EGFR)都过度表达,从而引起癌变。靶向EGFR药物主要有两类:一类是作用于受体胞内区的小分子酪氨酸激酶抑制剂(TKI);另一类是作用于受体胞外区的单克隆抗体(MAb)。已经应用于临床的第一代EGFR抑制剂如易瑞沙、埃罗替尼、拉帕替尼等,它们对于NSCLC肺癌的治疗取得了很大的成功,提高了非小细胞肺癌患者五年的生存率。同时,与化疗相比,它们的优势在于不会产生骨髓抑制,恶心和神经毒性等副作用;但它们在单独治疗时药效较低,且有非常明显的皮疹和腹泻等副作用,而且在使用一年后,患者对药物出现耐药性。研究认为EGFR基因T790M位点的突变是此类药物耐药的主要诱因,有临床案例数据显示,大约有50%的患者获得性耐药都源于T790M位点的突变所致。进一步研究证实,由于EGFR基因T790M突变,即编码的苏氨酸转变为甲硫氨酸,从而造成了空间位阻阻碍了抑制剂与ATP结合区结合最终导致了抑制剂活性丧失。目前也有研究显示T790M位点的突变不是直接影响抑制剂与EGFR的亲和性,而是突变导致EGFR与ATP的亲和性大大增加,使得抑制剂与EGFR的亲和性相对的大大降低了(抑制剂与ATP是竞争性结合)。第二代抑制剂如阿法替尼、Dacomitinib,它们优于第一代的特征在于对EGFR的识别性增加,可以辨别肿瘤细胞和正常细胞,这样副作用就会减少。但这些分子对EGFR的T790M突变体的选择性差,造成药物临床耐受剂量较低,在其最大耐受剂量(MTD)下,药物无法在体内达到其有效浓度而使得对多数耐药病人无效。
总之,目前的EGFR-TKI仍不能解决药物耐药性所引起的临床需求,而且现有的药物多是以喹唑啉或者喹啉胺类为基本母核的EGFR可逆或不可逆抑制剂,其对野生型细胞的选择性差带来的毒副作用也是不可避免的。因此,临床上迫切需要新类型,尤其是新颖骨架的化合物来解决耐药性、选择性差等问题。
发明内容
本发明的目的是提供一类氘代3-(4,5-取代氨基嘧啶)苯基衍生物。
本发明的目的可以通过以下措施达到:
本发明的氘代3-(4,5-取代氨基嘧啶)苯基衍生物为具有式(I)结构的化合物或其药学上可接受的盐,
其中,R1,R2,R3及R4独立地选自-CH3或-CD3,且R1,R2,R3及R4至少一个为-CD3。
进一步地,所述的具有式(I)结构的化合物,优选R1为-CH3。
本发明的化合物或其药学上可接受的盐,其中一些具体化合物选自:
具有通式(I)的化合物制备路线如下所示:
上述制备路线的具体步骤如下:
步骤1:以二甲醚(DME)为溶剂,化合物II与2,4-二氯嘧啶在三氯化铝等路易斯酸的存在下,通过亲核取代反应得到III。
步骤2:中间体III与4-氟-2-甲氧基-5-硝基苯胺在对甲苯磺酸作用下得到IV。
步骤3:以1,4-二氧六环为溶剂,中间体IV和氘代有机胺在DIPEA的作用下反应得到中间体V。
步骤4:以甲醇或乙醇作为溶剂,以Pd/C为还原剂,将中间体V还原为中间体VI。
步骤5:以THF/H2O为溶剂,中间体VI与氯丙酰氯反应得到中间化合物,不分离,直接加氢氧化钠继续反应得到最终产品式I化合物。
本发明中的化合物可能形成的盐也是属于本发明的范围。除非另有说明,本发明中的化合物被理解为包括其盐类。例如,通式(I)的化合物与一定量如等当量的酸或碱反应,在介质中盐析出来,或在水溶液中冷冻干燥得来。本发明中的化合物含有的碱性片段,包括但不限于胺或吡啶或咪唑环,可能会和有机或无机酸形成盐。可以成盐的典型的酸包括醋酸盐、己二酸盐、藻朊酸盐、抗坏血酸盐、天冬氨酸盐、苯甲酸盐、苯磺酸盐、对甲苯磺酸盐、硫酸氢盐、硼酸盐、丁酸盐、柠檬酸盐、樟脑盐、樟脑磺酸盐、环戊烷丙酸盐、二甘醇酸盐、十二烷基硫酸盐、乙烷磺酸盐、延胡索酸盐、葡庚糖酸盐、甘油磷酸盐、庚酸盐、己酸盐、盐酸盐、氢溴酸盐、氢碘酸盐、羟基乙磺酸盐、乳酸盐、马来酸盐、甲磺酸盐、萘磺酸盐、烟酸盐、硝酸盐、草酸盐、果胶酸盐、过硫酸盐、苯丙酸盐、磷酸盐、苦味酸盐、新戊酸盐、丙酸盐,水杨酸盐、琥珀酸盐、硫酸盐、磺酸盐、酒石酸盐、硫氰酸盐。
本发明中的化合物,依次通过制备、分离纯化获得的该化合物其重量含量等于或大于90%,例如,等于或大于95%,等于或大于99%(“非常纯”的化合物),在正文描述列出。此处这种“非常纯”本发明的化合物也作为本发明的一部分。
本发明还公开了所述通式(I)的化合物或其药学上可接受的盐在制备或预防肿瘤药物中的应用。
所述肿瘤选自非小细胞肺癌、小细胞肺癌、胰腺癌、乳腺癌、***癌、肝癌、皮肤癌、上皮细胞癌、胃肠间质瘤、白血病、组织细胞性淋巴癌、鼻咽癌。
本发明的一个方面提供式(I)的化合物,用于治疗或预防由EGFR介导的或由激活突变体或抗性突变体形式的EGFR介导的疾病、障碍、紊乱或病况。
由EGFR介导的或由激活突变体或抗性突变体形式的EGFR介导的疾病、障碍、紊乱或病况选自非小细胞肺癌、小细胞肺癌、胰腺癌、乳腺癌、***癌、肝癌、皮肤癌、上皮细胞癌、胃肠间质瘤、白血病、组织细胞性淋巴癌或鼻咽癌。
所述激活突变体或抗性突变体形式的EGFR选自L858R激活突变体、Exon19缺失激活突变体和T790M抗性突变体。
本发明通式(I)的化合物可以与已知的治疗或改进相似病状的其他药物联用。联合给药时,原来药物的给药方式和剂量保持不变,而同时或随后服用式(I)的化合物。当式(I)化合物与其它一种或几种药物同时服用时,优选使用同时含有一种或几种已知药物和式(I)化合物的药用组合物。药物联用也包括在重叠的时间段服用式(I)化合物与其它一种或几种已知药物。当式(I)化合物与其它一种或几种药物进行药物联用时,式(I)化合物或已知药物的剂量可能比它们单独用药时的剂量低。可以与式(I)化合物进行药物联用的药物或活性成分包括但不局限于以下物质:
***受体调节剂、雄激素受体调剂、视网膜受体调节剂、细胞毒素/细胞抑制剂、抗增殖剂、蛋白转移酶抑制剂、HMG-CoA还原酶抑制剂、HIV蛋白激酶抑制剂、逆转录酶抑制剂、血管生成抑制剂、细胞增殖及生存信号抑制剂、干扰细胞周期关卡的药物和细胞凋亡诱导剂,细胞毒类药物、酪氨酸蛋白抑制剂、EGFR抑制剂、VEGFR抑制剂、丝氨酸/苏氨酸蛋白抑制剂、Bcr-Abl抑制剂,c-Kit抑制剂、Met抑制剂、Raf抑制剂、MEK抑制剂、MMP抑制剂、拓扑异构酶抑制剂、组氨酸去乙酰化酶抑制剂、蛋白体酶抑制剂、CDK抑制剂、Bcl-2家族蛋白抑制剂、MDM2家族蛋白抑制剂、IAP家族蛋白抑制剂、STAT家族蛋白抑制剂、PI3K抑制剂、ATK抑制剂、整联蛋白阻滞剂、干扰素、白介素-12、COX-2抑制剂、P53、P53激活剂、VEGF抗体和EGF抗体等。
在一个实施方案中,可以与式(I)化合物进行药物联用的药物或活性成分包括但不局限于以下物质:阿地白介素、阿仑膦酸、干扰素、阿曲诺英、别嘌醇、别嘌醇钠、帕洛诺司琼盐酸盐、六甲蜜胺、氨基格鲁米特、安磷汀、安柔比星、安丫啶、阿纳托唑、多拉司琼、aranesp、arglabin、三氧化二砷、阿诺新、5-氮胞苷、硫唑嘌呤、卡介苗或tice卡介苗、贝他定、醋酸倍他米松、倍他米松磷酸钠抑制剂、贝沙罗汀、硫酸博来霉素、溴尿甘、硼替佐米、卡菲左米、白消安、降钙素、阿来佐单抗注射剂、卡培他滨、卡铂、康士得、cefesone、西莫白介素、柔红霉素、苯丁酸氮芥、顺铂、克拉屈滨、氯屈磷酸、环磷酰胺、阿糖胞苷、达卡巴嗪、放线菌素D、柔红霉素脂质体、***、磷酸***、戊酸***、地尼白介素2、狄波美、地洛瑞林、地拉佐生、乙烯雌酚、大扶康、多西他奇、去氧氟尿苷、阿霉素、屈***酚、钦-166-壳聚糖复合物、eligrand、拉布立酶、盐酸表柔比星、阿瑞吡坦、表阿霉素、阿法依伯汀、红细胞生成素、依铂、左旋咪唑片、***抑制剂、17-立酶***、雌莫司汀磷酸钠、雌炔醇、氨磷汀、羟磷酸、凡毕复、依托泊甙、法倔唑、他莫西芬制剂、非格司亭、非那司提、非雷司替、氟尿苷、氟康唑、氟达拉滨、5-氟脱氧尿嘧啶核苷一磷酸盐、5-氟尿嘧啶、氟***、氟他胺、福麦斯坦、1-嘧啶、阿糖呋喃糖胞噻啶-5呋喃硬质酰磷酸酯、福莫司汀、氟维司琼、丙种球蛋白、吉西他滨、吉妥单抗、甲磺酸伊马替尼、卡氮芥糯米纸胶囊、戈舍林瑞、盐酸拉格尼西陇、组胺瑞林、和美新、氢化可的松、赤型-羟基壬基腺嘌呤、羟基脲、替坦异贝莫单抗、伊达比星、异环磷酰胺、白细胞介素-2,内含子A、易瑞沙、依立替康、凯特瑞、硫酸香菇多糖、来曲唑、甲酰四氢叶酸、亮丙瑞林、亮丙瑞林醋酸盐、左旋四咪唑、左旋亚叶酸钙盐、左甲状腺素钠、左甲状腺素钠制剂、洛莫司汀、氯尼达明、屈***酚、氮芥、甲钴胺、甲羟孕酮醋酸酯、醋酸甲地孕酮、美法仑,酯化***、6-巯基嘌呤、美司钠、氨甲喋呤、氨基乙酰丙酸甲酯、来替福新、美满霉素、丝裂霉素C、米托坦、米托葱醌、曲洛司坦、柠檬酸阿霉素脂质体、奈达铂、聚乙二醇化非格司亭、奥普瑞白介素、neupogen、尼鲁米特、三苯氧胺、NSC-631570、重组人白细胞介素1-组、奥曲肽、盐酸奥丹西隆、去氢氢化可的松口服溶液剂、奥沙利铂、紫杉醇、***磷酸钠制剂、培门冬酶、派罗欣、喷司他丁、溶链菌制剂、盐酸匹鲁卡品、毗柔比星、普卡霉素、卟吩姆钠、泼尼莫司汀、司替***龙、***、倍美力、丙卡巴脐、重组人类红细胞生成素、雷提曲赛、利比、依替磷酸铼-186、美罗华、力度伸-美、罗莫肽、盐酸毛果芸香碱片剂、奥曲肽、沙莫司亭、司莫司汀、西佐喃、索布佐生、唬钠甲强龙、帕福斯酸、干细胞治疗、链佐星、氯化锶-89、左旋甲状腺素钠、他莫昔芬、坦舒洛辛、他索那明、tastolactone、泰索帝、替西硫津、替莫唑胺、替尼泊苷、丙酸睾酮、硫鸟嘌呤、噻替哌、促甲状腺激素、替鲁磷酸、拓扑替康、托瑞米芬、托西莫单抗、曲妥珠单抗、曲奥舒凡、维A酸、甲胺碟呤片剂、三甲基密胺、三甲曲沙、乙酸曲普瑞林、双羟萘酸曲普瑞林、优福啶、尿苷、戊柔比星、维司力农、长春碱、长春新碱、长春酰胺、长春瑞滨、维鲁利秦、右旋丙亚胺、净司他丁斯酯、枢复宁、紫杉醇蛋白稳定制剂、acolbifene、affinitak、氨基碟呤、阿佐昔芬、asoprisnil、阿他美坦、BAY43-9006、阿瓦斯丁、CCI-779、CDC-501、西乐葆、西妥昔单抗、克拉那托、环丙孕酮醋酸酯、地西他滨、DN-101/阿霉素-MTC、dSLIM、度他雄胺、edotecarin、依氟鸟氨酸、依喜替康、芬维A胺、组胺二盐酸盐、组胺瑞林水凝胶植入物、钬-166DOTMP、伊班磷酸、ixabepilone、匙孔形血蓝蛋白、L-651582、兰乐肽、拉索昔芬、libra、lonafamib、米泼昔芬、米诺屈酸酯、MS-209、脂质体MEP-PE、MX-6、那法瑞林、奈莫柔比星、新伐司他、诺拉曲特、奥利默森、onco-TCS、osidem、紫杉醇聚谷氨酸酯、帛米酸钠、PN-401、OS-21、夸西洋、R-1549、雷洛昔芬、豹蛙酶、13-顺维A酸、沙铂、西奥骨化醇、T-138067、tarceva、二十二碳六烯酸紫杉醇、胸腺素α、嘎唑呋林、tipifarnib、替拉孔明、TLK-286、托瑞米芬、反式MID-lo7R、伐司朴达、伐普肽、vatalanob、维替泊芬、长春氟宁、Z-100和唑来磷酸或他们的组合。
本发明还提供了一种药物组合物,该药物组合物包括所述式(I)的化合物或其药学上可接受的盐和药学上可接受的辅料或载体。这里所用的短语“药学上可接受的辅料或载体”是指药学接受的材料、成份或介质,如液体或固体填料、稀释剂、辅料、溶剂或封装材料,包括从一个器官或身体的某部分到另一个器官或身体的某部分携带或运输主要药学试剂。每个载体必须是“可以接受”,能兼容其他形式的药物成份而对病人不造成伤害。一些可作为药学上可以接受的载体的例子包括:糖,如乳糖、葡萄糖和蔗糖糖;淀粉,如小麦淀粉和马铃薯淀粉淀粉;纤维素及其衍生物,如钠羧甲基纤维素、乙基纤维素、醋酸纤维素,粉状西黄蓍胶、麦芽、明胶、滑石粉;辅料,如可可黄油和栓剂蜡;油,如花生油、棉籽油、红花油、芝麻油、橄榄油、玉米油和豆油;甘醇,如丁二醇;多元醇,如甘油、山梨醇、甘露醇和聚乙二醇;酯,如油酸乙酯和月桂酸乙酯;琼脂;缓冲剂,如氢氧化镁和氢氧化铝;海藻酸;无热原水;生理盐水;林格氏液;乙醇;磷酸盐缓冲液,以及其他无毒的应用在药物制剂的可兼容物质。
当本发明的化合物作为药剂给人类和动物进行治疗时,它们可以本身或作为药物组合物而给药。例如,包含0.1%-99.5%(优选是0.5%-90%)的活性成分和药学上可接受的载体。
本发明的化合物可通过静脉注射,肌肉注射,腹腔注射,皮下注射,外用,口服,或其他可接受的办法来治疗疾病。
本发明还提供了药品包装或套件,包括一个或多个的包装,其中含有对本发明中一个或多个成分的药物组合。可选的此类包装以公告的形式由政府机构规范生产,以生产法规中许可的公开方法使用或销售药品或生物制品,使用或销售对人的治疗制剂。
与现有技术相比,本发明的有益效果为:
本发明的氘代化合物,具有与AZD9291相近的酶和细胞水平生物活性且具有更低的心脏毒性。本发明的氘代化合物为新型抗肿瘤药物提供了更多的选择,具有良好的药物应用前景。
具体实施方式
下面有代表性的例子旨在帮助阐述本发明,而不是有意也不应该被解释为限制本发明的范围。事实上,除了那些出现和描述于此的以外,本发明中文件的全部内容,包括依据此处引用的科技文献和专利的例子,以及由此产生的各种修饰和许多进一步变化对本专业内一般技术人员都是清晰明白的。还应当明白,这些参考文献的引用有助于陈述本文内容。下面的例子包含了重要的补充信息、范例和指导,可适应于本发明中各种变化及类似情况。
实施例1
合成路线如下:
化合物1
取250mL单口烧瓶,分别加入N-甲基乙醇胺(10g,133.1mmol)、TEA(26.9g,266.3mmol)、乙腈(100mL),然后将氯化苄(23.9g,139.8mmmol)在0℃下慢慢滴加到反应液中,并在室温下继续搅拌1h,TLC监测无原料剩余,减压蒸馏除去溶剂,柱层析纯化得到21g无色液体即化合物1,收率95.5%。
化合物2
取250mL茄型瓶,加入化合物1(21g,127.1mmol)、TEA(25.7g,254.2mmol)和DCM(100ml),然后在0℃下滴加MsCl(14.6g,127.1mmol)。反应液在室温下搅拌3h,TLC监测已无原料剩余,减压蒸馏除去溶剂,柱层析纯化得到20g淡黄色液体即化合物2,收率85.6%。
化合物3
取500mL封管,加入化合物2(20g,108.9mmol),氨水215mL,混合液在40℃下搅拌过夜,TLC监测已无原料剩余,柱层析纯化得到15g无色液体即化合物3,收率为84%。
化合物4
取500mL茄型瓶,加入化合物3(15g,91.3mmol)、DCM(200mL),在室温下慢慢滴加Boc2O(19.9g,91.3mmol),滴加完毕后混合液在室温下继续搅拌3h,TLC监测无原料剩余,减压蒸馏除去溶剂,柱层析纯化得到21g化合物4,为白色固体,产率为87%。
化合物5
取100mL茄型瓶,加入化合物4(10g,37.8mmol)、DMF(40mL),然后分批加入NaH(2.3g,56.7mmol),搅拌30mins,加入TsOCD3(7.9g,41.6mmol)的DMF(10mL)溶液,然后室温下搅拌3h,TLC监测无原料剩余,加入150mL H2O淬灭,EA(50mL*3)萃取,合并有机相,brine洗,无水Na2SO4干燥,减压蒸馏出去溶剂,柱层析纯化得到8.5g即化合物5,为白色固体,收率为80%。
化合物6
取250mL茄型瓶,加入化合物5(8.5g,30.18mmol)、THF(80ml),冰浴下分批加入LiAlH4(3.4g,90.59mmol),然后加热到60℃过夜,TLC监测无原料剩余,缓慢加入Na2SO4·10H2O淬灭,过滤除掉固体,收集滤液,减压蒸馏除去溶剂,柱层析纯化得到4.5g无色液体即化合物6,收率为76.3%。
化合物7
取100mL茄型瓶,分别加入化合物6(4.5g,23mmol)、MeOH(50mL)、Pd(OH)2/C(200mg),抽真空换氢气3次,室温下搅拌过夜,TLC监测已无原料剩余,过滤除掉Pd(OH)2/C,然后将反应液pH值调到酸性,减压蒸馏除去溶剂得到2.8g白色固体即化合物7,收率85.9%。
化合物8
取250mL茄型瓶,分别加入2,4-二氯嘧啶(11.37g,76.33mmol)、AlCl3(10.18g,76.33mmol)和100mLDME,室温下搅拌20分钟。然后分批加入化合物8-01(10.00g,63.61mmol),升至80度反应6h。停止反应冷却至室温,加入100毫升水,搅拌2h,过滤,固体用乙醇洗涤,真空干燥得红色粗品15.46克即化合物8-02,得率90.1%。
取300mL1,4-二氧六环于500mL茄型瓶中,分别加入化合物8-02(20.00g,82.07mmol)、化合物8-03(16.80g,90.28mmol)和对甲苯磺酸(17.17g,90.28mmol)。升至85度反应8h,冷却至室温,加水搅拌,并滴加40%氢氧化钠溶液至pH=9.过滤,固体用乙醇洗涤,真空干燥后得黄色固体30.00g即化合物8,得率92.9%。
化合物9
取120mL封管,加入化合物8(2g,4.77mmol)、7(810mg,5.72mmol)、DIPEA(1.23g,9.54mmol)、DMA(10mL)。然后封管140℃反应6h,TLC监测无原料剩余,将反应液冷却至室温,加入20mL水,析出固体,过滤,然后加入将滤饼加入2mL甲醇打浆洗涤,过滤、烘干得到1.7g红色固体即化合物9,收率70.6%。
化合物10
取250mL单口烧瓶,加入化合物9(1.7g,3.37mmol)、Pd/C(200mg)、MeOH(100mL),抽真空换氢气3次,室温下搅拌过夜,TLC监测已无原料剩余,过滤除掉Pd/C,减压蒸馏除去溶剂得到黄绿色固体,柱层析纯化,洗脱剂(DCM:MeOH:NH3H2O=20:1:0.1)洗脱,得到1.2g黄绿色固体即化合物10,收率75%。
化合物11
取20mL单口烧瓶,加入化合物10(500mg,1.05mmol)、DCM(30mL),然后将3-氯丙酰氯(133.7mg,1.05mmol),在0℃下慢慢滴加到反应液中,并在室温下继续搅拌30min,TLC监测无原料剩余,然后加入NaOH(168mg,4.2mmol),升温到65℃搅拌过夜,HPLC监测无原料剩余,减压蒸馏除去溶剂,柱层析纯化,洗脱剂(DCM:MeOH=10:1)洗脱得到280mg淡黄色固体即化合物11,收率为50.4%。
1H NMR(400MHz,CDCl3)δ10.19(s,1H),9.88(s,1H),9.12(s,1H),8.39(d,J=5.3Hz,1H),7.85(d,J=8.0Hz,1H),7.74(s,1H),7.26–7.14(m,2H),7.00(d,J=7.0Hz,1H),6.82(s,1H),6.49(dd,J=16.9,2.2Hz,1H),6.39(dd,J=16.9,9.8Hz,1H),5.73(dd,J=9.8,2.2Hz,1H),4.49–4.32(m,2H),3.91(s,3H),3.05(t,J=6.0Hz,2H),2.95–2.87(m,2H),2.73(s,3H),2.39–2.23(m,7H),1.82(s,3H).LC-MS[M+H]+528.7
实施例2
合成路线如下:
化合物12
取120mL封管,加入化合物8(500mg,1.19mmol)、N-甲基乙醇胺(107.26mg,1.42mmol)、DIPEA(307.59mg,2.38mmol)、DMA(5mL)。然后封管140℃反应6h,TLC监测无原料剩余,将反应液冷却至室温,加入20mL水,析出固体,过滤,然后加入将滤饼加入2mL甲醇打浆洗涤,过滤、烘干得到480mg红褐色固体即化合物12,收率85%。
化合物13
取20mL茄型瓶,加入化合物12(450mg,1.05mmol)、TEA(159.39mg,1.57mmol)和DCM(5ml)。0℃下慢慢滴加MsCl(120.28mg,1.05mmol),滴加完毕后在该温度下搅拌,1h后TLC监测已无原料剩余,减压蒸馏除去溶剂,柱层析纯化得到320mg红色固体即化合物13,收率55.15%。
化合物14
取5mL封管,加入化合物13(220mg,0.40mmol)、氘代二甲胺(175.16mmg,2mmol)、DIPEA(103.39mg,0.8mmol)、THF(2mL),80℃下搅拌过夜,TLC监测已无原料剩余,减压蒸馏除去溶剂得到红色固体,柱层析纯化,洗脱剂(DCM:MeOH:NH3H2O=40:1:0.1)洗脱,得到90mg红色固体即化合物14,收率44.32%。
化合物15
取250mL单口烧瓶,加入化合物14(90mg,0.18mmol)、Pd/C(30mg)、MeOH(10mL),抽真空换氢气3次,室温下搅拌过夜,TLC监测已无原料剩余,过滤除掉Pd/C,减压蒸馏除去溶剂得到黄绿色固体,柱层析纯化,洗脱剂(DCM:MeOH:NH3H2O=20:1:0.1)洗脱,得到40mg黄绿色固体即化合物15,收率46.53%。
化合物16
取10mL单口烧瓶,加入化合物15(40mg,0.08mmol)、DCM(4mL),然后将3-氯丙酰氯(10.63mg,0.08mmol)在0℃下慢慢滴加到反应液中,并在室温下继续搅拌30min,TLC监测无原料剩余,然后加入NaOH(16mg,0.4mmol),升温到65℃搅拌过夜,HPLC监测无原料剩余,减压蒸馏除去溶剂,柱层析纯化,洗脱剂(DCM:MeOH:NH3H2O=40:1:0.1)洗脱得到38mg淡黄色固体即化合物16,收率为89.34%。
1H NMR(400MHz,CDCl3)δ10.12(s,1H),9.88(s,1H),9.10(s,1H),8.39(d,J=5.2Hz,1H),7.86(d,J=8.0Hz,1H),7.74(s,1H),7.19(dd,J=17.1,6.5Hz,2H),7.00(d,J=6.9Hz,1H),6.81(s,1H),6.46(d,J=8.4Hz,2H),5.73(dd,J=8.6,3.1Hz,1H),4.51–4.28(m,2H),3.90(s,3H),3.05(t,J=5.6Hz,2H),2.98–2.87(m,2H),2.72(s,3H),2.31(dd,J=16.4,11.2Hz,4H).LC-MS[M+H]+531.7
实施例3
合成路线如下:
化合物17
取2L三颈瓶,分别加入CD3OH(15g,415.8mmol)、THF(600mL)。然后在-40℃下慢慢滴加n-BuLi(174.6mL,436.6mmol)。搅拌1h后滴加TsCl(79.3g,415.8mmol)的四氢呋喃溶液,滴加完毕后继续搅拌3h,TLC监测无原料剩余。加入600mLH2O淬灭,EA萃取(200mL*3),brine洗涤,无水Na2SO4干燥,合并有机相,减压蒸馏除掉溶剂得到粗化合物,柱层析纯化得到73克白色固体即化合物17,收率92.7%。
化合物18
取250mL茄型瓶,分别加入化合物17(8g,42.3mmol)、N-苄基乙醇胺(5.3g,35.2mmol)、三乙胺(9.8ml,70.4mmol)、四氢呋喃(100mL)。混合液在回流下反应8h,TLC监测无原料剩余,减压蒸馏除去溶剂,柱层析纯化得到5g无色粘稠液体即化合物18,收率84.4%。
化合物19
取50mL茄型瓶,分别加入化合物18(3g,15.87mmol)、三乙胺(3.2g,31.74mmol)、二氯甲烷(20mL),然后在0℃下慢慢滴加甲烷磺酰氯(2.18g,19.05mmol),反应液在室温下搅拌3h,TLC监测无原料剩余,减压蒸馏除去溶剂得到淡黄色粘稠液体,柱层析纯化得到2.8g淡黄色液体即化合物19,收率71.6%。
化合物20
取10mL封管,分别加入化合物19(2.8g,11.37mmol)、二甲胺溶液(1.5mL)、THF(3mL)。混合液在80℃下搅拌5h,TLC监测无原料剩余。加入5mL水稀释,乙酸乙酯(5mL*3),合并有机相,饱和食盐水洗涤,无水Na2SO4干燥,减压蒸馏除去溶剂,中压制备纯化得到2g无色液体即化合物20,收率75%。
化合物21
取100mL茄型瓶,分别加入化合物20(2g,10.2mmol)、10%钯碳(500mg)、甲醇(30mL),35℃氢气下搅拌过夜,TLC监测无原料剩余,滤掉固体,在滤液中滴加HCl(in EA)至pH为酸性,减压蒸馏除去溶剂得到900mg白色固体即化合物21,收率62.3%。
化合物22
取120mL封管,加入化合物8(965mg,2.3mmol)、21(467mg,2.76mmol)、二异丙基乙胺(1.18g,9.2mmol)、DMA(5mL)。然后封管140℃反应6h,TLC监测无原料剩余,将反应液冷却至室温,加入20mL水,析出固体,过滤,然后加入将滤饼加入2mL甲醇打浆洗涤,过滤、烘干得到900mg红色固体即化合物22,收率77.5%。
化合物23
取250mL单口烧瓶,加入化合物22(900mg,1.78mmol)、Pd/C(300mg)、MeOH(100mL),抽真空换氢气3次,室温下搅拌过夜,TLC监测已无原料剩余,过滤除掉Pd/C,减压蒸馏除去溶剂得到黄绿色固体,柱层析纯化,洗脱剂(DCM:MeOH:NH3H2O=20:1:0.1)洗脱,得到600mg黄绿色固体即化合物23,收率71%。
化合物24
取20mL单口烧瓶,加入化合物23(300mg,0.63mmol)、THF(6mL)和H2O(1mL),然后将3-氯丙酰氯(80.36mg,0.63mmol)在0℃下慢慢滴加到反应液中,并在室温下继续搅拌30min,TLC监测无原料剩余,然后加入NaOH(100.8mg,2.52mmol),升温到65℃搅拌过夜,HPLC监测无原料剩余,减压蒸馏除去溶剂,柱层析纯化,洗脱剂(DCM:MeOH=10:1),洗脱得到170mg淡黄色固体即化合物24,收率51%。
1H NMR(400MHz,CDCl3)δ10.07(s,1H),9.87(s,1H),9.10(s,1H),8.39(d,J=5.3Hz,1H),7.85(d,J=8.0Hz,1H),7.75(s,1H),7.25–7.14(m,2H),7.00(d,J=7.0Hz,1H),6.80(s,1H),6.57–6.38(m,2H),5.74(dd,J=8.2,3.8Hz,1H),4.49–4.30(m,2H),3.91(s,3H),3.05(t,J=6.0Hz,2H),2.98–2.89(m,2H),2.42–2.21(m,13H).LC-MS[M+H]+528.7
实施例4:制备的化合物的生物活性测试
此类化合物对EGFR野生型、EGFR(T790M,L858R)双突变型以及EGFR(L858R)单突变型的激酶活性IC50测试。上述激酶采购于英潍捷基(上海)贸易有限公司。
采用均相时间分辨荧光(HTRF)的方法建立EGFR野生型、EGFR(T790M,L858R)双突变型以及EGFR(L858R)单突变型的激酶活性检测方法,测定化合物的抑制活性。配置8uL的反应液,包括1×enzymatic buffer(Cisbio,HTRF KinEASETM-TK),5mM MgCl2,1mM MnCl2,1mM DTT,0.5μM TK substrate-biotin(Cisbio,HTRF KinEASETM-TK)10μM ATP,梯度浓度的化合物以及0.04ng/μL EGFR或者0.025ng/μL的EGFR(T790M,L858R)或EGFR(L858R)。化合物反应浓度为1000nM起3倍稀释9个浓度。反应体系中DMSO浓度为2%。酶和化合物预孵育15分钟,然后加入ATP和底物开始反应。所有酶催化反应都在25℃下进行60分钟。酶催化反应结束后,反应液中加入4μL TK antibody-cryptate和4μL streptavidin-XL665(反应浓度为62.5nM),继续在25℃孵育60分钟。孵育结束后在CLARIOstar(BMG LABTECH)上检测HTRF荧光值,并使用GraphPad Prism 5.0计算IC50。
表1体外酶学活性测试数据(IC50,nM)
本发明的氘代化合物,具有与AZD9291相近的酶生物活性。
EGFR野生型,EGFR Exon19缺失(激活单突变体)以及EGFR(T790M,L858R)双突变型细胞磷酸化测试
测验1:EGFR野生型细胞磷酸化测验
人皮肤鳞状细胞癌细胞系A431表达野生型EGFR,从中国科学院细胞库购买。将A431维持在含有10%胎牛血清的EMEM培养基中。使细胞在有5%CO2的加湿培养箱中于37℃生长。依照Phospho-EGFR HTRF kit(Cisbio,货号#64HR1PEG)中描述的方案,检测细胞裂解液中内源性p-EGFR。将100μL细胞接种于96孔板中(50000细胞/孔),于37℃,5%CO2细胞培养箱中培养过夜。将连续4倍稀释的化合物加入细胞中,反应最高浓度为10μM。继续培养2小时后,加入100ng/孔的EGF于37℃培养10分钟,然后弃去培养液,并立即加入25μL/孔裂解液,于室温裂解细胞10分钟,然后取12μL/孔加入Greiner白色低体积384孔板中,加入检测抗体(Anti-phospho EGFR-d2以及Anti-EGFR-Tb),在25℃孵育60分钟。孵育结束后在CLARIOstar(BMG LABTECH)上检测HTRF荧光值,并使用GraphPad Prism 5.0计算IC50。
测验2:Exon19缺失EGFR(激活单突变体)细胞磷酸化测验
人非小细胞肺癌细胞系HCC827(Exon19缺失EGFR,激活单突变体)从中国科学院细胞库购买。将HCC827维持在含有10%胎牛血清RPMI1640培养基中。使细胞在有5%CO2的加湿培养箱中于37℃生长。依照Phospho-EGFR HTRF kit(Cisbio,货号#64HR1PEG)中描述的方案,检测细胞裂解液中内源性p-EGFR。将100μL细胞接种于96孔板中(50000细胞/孔),于37℃,5%CO2细胞培养箱中培养过夜。将连续4倍稀释的化合物加入细胞中,反应最高浓度为10μM。继续培养2小时后弃去培养液,并立即加入25μL/孔裂解液,于室温裂解细胞10分钟,然后取12μL/孔加入Greiner白色低体积384孔板中,加入检测抗体(Anti-phosphoEGFR-d2以及Anti-EGFR-Tb),在25℃孵育60分钟。孵育结束后在CLARIOstar(BMG LABTECH)上检测HTRF荧光值,并使用GraphPad Prism 5.0计算IC50。
测验3:EGFR(T790M,L858R)双突变型细胞磷酸化测验
人非小细胞肺癌细胞系NCI-H1975表达EGFR(T790M,L858R)双突变型,从中国科学院细胞库购买。将NCI-H1975维持在含有10%胎牛血清RPMI1640培养基中。使细胞在有5%CO2的加湿培养箱中于37℃生长。依照Phospho-EGFR HTRF kit(Cisbio,货号#64HR1PEG)中描述的方案,检测细胞裂解液中内源性p-EGFR。将100μL细胞接种于96孔板中(50000细胞/孔),于37℃,5%CO2细胞培养箱中培养过夜。将连续4倍稀释的化合物加入细胞中,反应最高浓度为10μM。继续培养2小时后弃去培养液,并立即加入25μL/孔裂解液,于室温裂解细胞10分钟,然后取12μL/孔加入Greiner白色低体积384孔板中,加入检测抗体(Anti-phosphoEGFR-d2以及Anti-EGFR-Tb),在25℃孵育60分钟。孵育结束后在CLARIOstar(BMG LABTECH)上检测HTRF荧光值,并使用GraphPad Prism 5.0计算IC50。
表2细胞水平EGFR野生及突变体磷酸化测试(IC50,nM)
本发明的氘代化合物,具有与AZD9291相近的细胞水平生物活性。
实施例9:制备的化合物对hERG钾离子通道作用的测试
稳定表达hERG通道的HEK293细胞培养于35mm培养皿中,在37℃/5%CO2培养箱中放置至少24小时后用于实验。细胞培养基为含有10%胎牛血清和250μg/mL G418的DMEM。
全细胞膜片钳实验所用细胞外液的成分为(mM):NaCl,137;KCl,4;CaCl2,1.8;MgCl2,1;HEPES,10;glucose 10;pH 7.4(NaOH滴定)。所有测试化合物和对照化合物溶液均含0.3%DMSO。细胞内液(mM)为:K Aspartate,130;MgCl2,5;EGTA 5;HEPES,10;Tris-ATP4;pH 7.2(KOH滴定)。
每次实验取出一个培养皿,用细胞外液清洗两次,放置于倒置显微镜载物台上。全细胞膜片钳实验在室温下进行,所用硼硅玻璃微电极尖端电阻为3~5MΩ。全细胞记录模式后,将膜电位钳制在-80mV,每隔30s给予细胞+50mV去极化电压刺激,持续2s后复极化至-50mV,持续3s,即可引出hERG尾电流。去极化电压刺激前,先给予细胞50ms,-50mV复极化电压,该电压下记录的电流作为计算hERG尾电流的基线。加入化合物前,hERG尾电流在细胞外液中至少稳定记录3分钟。灌流给药后当hERG尾电流幅值变化小于<5%时,被认为药物作用达到稳态。数据采集和分析使用pCLAMP 10.1软件程序。选取加入化合物前电流处于稳态的4~5个sweep,计算峰值平均值,作为对照电流幅值。选取加入化合物后电流处于稳态的4~5个sweep,计算峰值平均值,作为电流被抑制后的剩余幅值。待测化合物对hERG电流的抑制率依据以下方程进行计算:
%抑制率={1-(电流剩余幅值)/(对照电流幅值)}×100
依据上述计算方法得到待测化合物多个浓度对hERG电流的抑制率(平均值±标准差)后,使用logistic方程对数据进行拟合,得到IC50值。
表3化合物在细胞水平对hERG钾离子通道抑制的IC50(μM)
Compound ID | IC50 |
AZD9291 | 0.37 |
化合物11 | 1.85 |
化合物16 | 2.67 |
化合物24 | 1.97 |
本发明的氘代化合物,相对于AZD9291具有更低的心脏毒性。
Claims (10)
1.具有式(I)结构的化合物或其药学上可接受的盐,
其中,
R1,R2,R3及R4独立地选自-CH3或-CD3,且R1,R2,R3及R4至少一个为-CD3。
2.根据权利要求1所述的具有式(I)结构的化合物,其特征在于R1为-CH3。
3.化合物或其药学上可接受的盐,其中化合物选自:
4.根据权利要求1~3中任一项所述的具有式(I)结构的化合物或其药学上可接受的盐,其中所述药学上可接受的盐选自醋酸盐、己二酸盐、藻朊酸盐、抗坏血酸盐、天冬氨酸盐、苯甲酸盐、苯磺酸盐、对甲苯磺酸盐、硫酸氢盐、硼酸盐、丁酸盐、柠檬酸盐、樟脑盐、樟脑磺酸盐、环戊烷丙酸盐、二甘醇酸盐、十二烷基硫酸盐、乙烷磺酸盐、延胡索酸盐、葡庚糖酸盐、甘油磷酸盐、庚酸盐、己酸盐、盐酸盐、氢溴酸盐、氢碘酸盐、羟基乙磺酸盐、乳酸盐、马来酸盐、甲磺酸盐、萘磺酸盐、烟酸盐、硝酸盐、草酸盐、果胶酸盐、过硫酸盐、苯丙酸盐、磷酸盐、苦味酸盐、新戊酸盐、丙酸盐,水杨酸盐、琥珀酸盐、硫酸盐、磺酸盐、酒石酸盐、硫氰酸盐。
5.一种药物组合物,其包括如权利要求1~4中任一项所述的具有式(I)结构的化合物或其药学上可接受的盐,以及药学上可接受的辅料。
6.权利要求1~4中任意一项所述的具有式(I)结构的化合物或其药学上可接受的盐在制备治疗或预防肿瘤药物方面的用途。
7.根据权利要求6所述的用途,其中所述肿瘤选自非小细胞肺癌、小细胞肺癌、胰腺癌、乳腺癌、***癌、肝癌、皮肤癌、上皮细胞癌、胃肠间质瘤、白血病、组织细胞性淋巴癌或鼻咽癌。
8.权利要求1~4中任一项所述的具有式(I)结构的化合物或其药学上可接受的盐在制备用于治疗或预防由EGFR介导的或由激活突变体或抗性突变体形式的EGFR介导的疾病、障碍、紊乱或病况的药物的用途。
9.根据权利要求8所述的用途,其中所述由EGFR介导的或由激活突变体或抗性突变体形式的EGFR介导的疾病、障碍、紊乱或病况选自非小细胞肺癌、小细胞肺癌、胰腺癌、乳腺癌、***癌、肝癌、皮肤癌、上皮细胞癌、胃肠间质瘤、白血病、组织细胞性淋巴癌或鼻咽癌。
10.根据权利要求8所述的用途,其中所述激活突变体或抗性突变体形式的EGFR选自L858R激活突变体、Exon19缺失激活突变体和T790M抗性突变体。
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610833361.3A CN107840847A (zh) | 2016-09-19 | 2016-09-19 | 氘代3‑(4,5‑取代氨基嘧啶)苯基衍生物及其应用 |
US16/333,700 US10654851B2 (en) | 2016-09-19 | 2017-09-18 | Deuterated 3-(4,5-substituted aminopyrimidine)phenyl derivatives and use thereof |
CN201780056474.XA CN109689657B (zh) | 2016-09-19 | 2017-09-18 | 氘代3-(4,5-取代氨基嘧啶)苯基衍生物及其应用 |
EP17850310.8A EP3498708B1 (en) | 2016-09-19 | 2017-09-18 | Deuterated 3-(4,5-substituted pyrimidinamine) phenyl derivatives and applications thereof |
KR1020197007580A KR102245280B1 (ko) | 2016-09-19 | 2017-09-18 | 중수소화 3-(4,5-치환 아미노피리미딘) 페닐 유도체 및 그의 응용 |
PCT/CN2017/102027 WO2018050108A1 (zh) | 2016-09-19 | 2017-09-18 | 氘代3-(4,5-取代氨基嘧啶)苯基衍生物及其应用 |
JP2019536634A JP6746794B2 (ja) | 2016-09-19 | 2017-09-18 | 重水素化3−(4,5−置換アミノピリミジン)フェニル誘導体及びその使用 |
CA3037097A CA3037097C (en) | 2016-09-19 | 2017-09-18 | Deuterated 3-(4,5-substituted aminopyrimidine) phenyl derivatives and use thereof |
AU2017326029A AU2017326029B2 (en) | 2016-09-19 | 2017-09-18 | Deuterated 3-(4,5-substituted pyrimidinamine) phenyl derivatives and applications thereof |
ES17850310T ES2863925T3 (es) | 2016-09-19 | 2017-09-18 | Derivados de 3-(pirimidinamina 4,5-sustituida)fenilo deuterados y aplicaciones de los mismos |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610833361.3A CN107840847A (zh) | 2016-09-19 | 2016-09-19 | 氘代3‑(4,5‑取代氨基嘧啶)苯基衍生物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107840847A true CN107840847A (zh) | 2018-03-27 |
Family
ID=61657288
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610833361.3A Pending CN107840847A (zh) | 2016-09-19 | 2016-09-19 | 氘代3‑(4,5‑取代氨基嘧啶)苯基衍生物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107840847A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019174623A1 (zh) * | 2018-03-16 | 2019-09-19 | 南京创特医药科技有限公司 | 氘代3-(4,5-取代氨基嘧啶)苯基化合物单甲磺酸盐晶型及其制备方法 |
-
2016
- 2016-09-19 CN CN201610833361.3A patent/CN107840847A/zh active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019174623A1 (zh) * | 2018-03-16 | 2019-09-19 | 南京创特医药科技有限公司 | 氘代3-(4,5-取代氨基嘧啶)苯基化合物单甲磺酸盐晶型及其制备方法 |
US11629144B2 (en) | 2018-03-16 | 2023-04-18 | Nanjing Chuangte Pharmaceutical Technology Co., Ltd | Crystal form of monomethanesulfonate of deuterated 3-(4,5-substituted aminopyrimidine)phenyl compound and preparation method therefor |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10183941B2 (en) | Pyrimidine or pyridopyridone compound and application thereof | |
EP2637502B1 (en) | Mutant-selective egfr inhibitors and uses thereof | |
CA3050188C (en) | Imidazopyrazine compounds, preparation methods and uses thereof | |
EP3312180B1 (en) | Use of pteridinone derivative serving as egfr inhibitor | |
EP3398950B1 (en) | Novel kinase inhibitor against wild-type egfr and mutated egfr | |
CN112724145A (zh) | 用于抑制shp2活性的吡嗪衍生物 | |
US20150152088A1 (en) | Alkynyl heteroaromatic compound and use thereof | |
CN101137382A (zh) | 含有杂环化合物作为活性成分的免疫抑制剂和抗肿瘤剂 | |
RU2744168C1 (ru) | Новое пиримидиновое производное, обладающее эффектом ингибирования роста раковых клеток, и содержащая его фармацевтическая композиция | |
US20150299202A1 (en) | Heteroaryl alkyne compound and use thereof | |
TW202104231A (zh) | 用於治療kit 及pdgfra 介導之疾病的組合物及方法 | |
WO2018191587A1 (en) | Tam kinase inhibitors | |
JP2022537876A (ja) | カゼインキナーゼ1ε阻害剤、医薬組成物及びその使用 | |
CN105884695B (zh) | 杂环衍生物类酪氨酸激酶抑制剂 | |
TW202035422A (zh) | 作為cdk抑制劑的大環化合物、其製備方法及其在醫藥上的應用 | |
CN109689657B (zh) | 氘代3-(4,5-取代氨基嘧啶)苯基衍生物及其应用 | |
EP3476848A1 (en) | Benzofuran pyrazole amine protein kinase inhibitor | |
WO2020232401A1 (en) | Combination therapies with ire1 small molecule inhibitors | |
CN107840847A (zh) | 氘代3‑(4,5‑取代氨基嘧啶)苯基衍生物及其应用 | |
CN111936470A (zh) | 用作fgfr不可逆抑制剂的酰胺基吡唑类化合物 | |
CN111362924B (zh) | 氘代的嘧啶衍生物及其用途 | |
CN112351971A (zh) | 喹啉或喹唑啉类化合物及其应用 | |
CN105541792B (zh) | 多环类pi3k抑制剂 | |
CN115708410A (zh) | 靶向降解Btk的化合物及其抗肿瘤用途 | |
CA3188077A1 (en) | Egfr inhibitor, preparation method therefor and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180327 |
|
WD01 | Invention patent application deemed withdrawn after publication |